|
Diamyd Medical AB - Company Profile Snapshot
| Company Profile: |
Diamyd Medical AB |
| Ticker: |
DIAM-B |
| Exchanges: |
STO OTH |
| 2009 Sales: |
1,105,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
SWEDEN |
| Employees: |
13 |
Business Description
Diamyd Medical AB. The Group's primary activity is the development of medicine for diabetes. The Group operates in two segments: GAD technology and NTDDS technology. The GAD technology segment comprises of GAD-protein and Diamyd anti-GAD RIA-kits. The products are sold to researchers and laboratories. The NTDDS segment include the Group's first drug candidate from theNerve Targeting Drug Delivery System (NTDDS) gene therapy platform. The Group operates globally.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
